Prior-Authorization Renewal Checklist for Crohn's and UC Medications

Most people with Crohn's disease or ulcerative colitis learn the prior authorization process the hard way, during the anxious weeks before a first dose of a biologic. What surprises them later is that the approval was temporary. Prior authorizations expire, usually after six or twelve months, and the renewal is a fresh review in which the insurer decides whether your treatment is still working well enough to keep paying for. A prior authorization renewal checklist for IBD medication is the practical defense against that review arriving unannounced, because the failure mode is rarely a hostile denial. It is a deadline nobody was watching, a records request nobody answered, and an infusion or shipment that quietly does not happen.

The stakes are higher than an inconvenience. In a systematic review and meta-analysis of anti-TNF discontinuation in IBD, roughly 44 percent of Crohn's patients and 38 percent of ulcerative colitis patients relapsed after stopping therapy, with relapse rates climbing the longer patients stayed off treatment. An administrative gap and a clinical decision to stop look the same to your immune system.

Why renewals are where treatment gaps happen

Renewals fail for structural reasons. In a national survey of gastroenterology providers, 93.8 percent reported a high or extremely high burden of prior authorization requests, and roughly half of all requests involved medication refills for patients already taking the drug. More than half of respondents said at least one of their patients had suffered a serious adverse event because of delays attributed to the process. A separate provider survey published in Clinical Gastroenterology and Hepatology reached the same conclusion, that prior authorizations delay therapy and lead to adverse events in inflammatory bowel disease.

Timing data explains the urgency. One IBD cohort found the average time from prior authorization submission to approval was 30.5 days, ranging as high as 145 days, with an average of 45.3 days from submission to first infusion. Approval was significantly slower for patients on Medicaid and Medicare than for those with private insurance. If your renewal is submitted the week your authorization ends, the arithmetic already works against you.

Find your actual expiration date

Your approval letter contains an authorization number and an end date, and that end date is the single most important thing to record. Ask your specialty pharmacy or infusion center to read it back to you, since they bill against it and will see a lapse before you do. Medicare Advantage enrollees have a specific protection worth knowing: under the 2024 Medicare Advantage final rule, approval of a prior authorization request for a course of treatment must be valid for as long as medically reasonable and necessary, and plans must provide a minimum 90-day transition period when an enrollee already undergoing treatment switches to a new plan, during which the new plan may not require prior authorization for the active course of treatment.

Two other dates belong beside the expiration date. The first is January 1, when formularies, tiers, and preferred biosimilars reset and an unchanged prescription can become a non-preferred drug. The second is any employer plan renewal date, which frequently differs from the calendar year.

Assemble the clinical evidence before you are asked

A renewal is a request to document continued response, so the file should show objective improvement rather than an assertion that you feel fine. Society guidance supports biomarker-based monitoring, which produces exactly the kind of numbers reviewers accept. The AGA guideline on biomarkers in ulcerative colitis suggests a biomarker- and symptom-based monitoring strategy for patients in remission, using fecal calprotectin under 150 micrograms per gram, normal lactoferrin, or normal C-reactive protein to rule out active inflammation. The companion Crohn's disease guideline reaches a parallel conclusion, that fecal calprotectin under 150 micrograms per gram with a normal CRP rules out active inflammation in asymptomatic patients.

Three items carry most of the weight in a renewal packet:

• Recent labs showing CRP and fecal calprotectin trends since starting the drug
• A symptom and dosing record demonstrating adherence and stable disease activity
• Clinic notes or endoscopy reports documenting response, plus drug level results if therapeutic drug monitoring was done

Work the renewal on a 90-day clock

Ninety days before expiration, confirm the date with the plan and ask what the reauthorization criteria require. Sixty days out, request labs so results are in the chart before submission, and confirm the prescribing office has started the paperwork. Thirty days out, verify the plan has received a complete submission, log the reference number, and ask the specialty pharmacy whether the next fill is already blocked.

Document every call with the date, the representative's name, and a reference number. Federal rules increasingly assume this level of specificity exists on both sides. Under the CMS Interoperability and Prior Authorization final rule, affected Medicare Advantage, Medicaid, CHIP, and Marketplace payers must send prior authorization decisions within 72 hours for expedited requests and seven calendar days for standard requests, and beginning in 2026 must give a specific reason for denials. Those provisions exclude decisions about drugs, so a specialty medication renewal may still follow the plan's own timeline, which makes your own log the reliable record.

If the renewal is denied

A denial at renewal starts the same appeal machinery as an initial denial, with deadlines that reward speed. For commercial and Marketplace coverage, insurers must notify you in writing within 15 days when you are seeking prior authorization for a treatment and within 72 hours for urgent care cases, and you have 180 days from that notice to file an internal appeal. If the internal appeal fails, you have four months to request an external review, decided no later than 45 days after receipt, or within 72 hours when expedited.

Medicare drug coverage runs on a different clock. You or your prescriber must request a redetermination within 65 days of the initial denial notice, with a standard decision due in 7 days and an expedited decision in 72 hours, followed by four further appeal levels. Ask the prescriber to request expedited handling whenever a lapse would interrupt maintenance dosing, since that argument is clinical rather than administrative.

Renewal is a scheduled event with predictable inputs. Expiration dates, lab timing, and appeal windows are knowable in advance, and each one lives somewhere different: a letter, a portal, a pharmacy record. Patients who keep those dates together, and who collect evidence of response throughout the year rather than in the week before submission, spend far less time arguing with a plan and far less time waiting for a dose that should never have been in question.